Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAE:JPH vs ZTS, UTHR, VTRS: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jerusalem Pharmaceutical Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jerusalem Pharmaceutical Co Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jerusalem Pharmaceutical Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Jerusalem Pharmaceutical Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jerusalem Pharmaceutical Co (XPAE:JPH) has a Buyback Yield % of 0.00 as of Aug. 13, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Jerusalem Pharmaceutical Co and its competitors. According to the industry distribution chart, Jerusalem Pharmaceutical Co ranks #999999 out of 271 companies in the Drug Manufacturers industry.
Is Jerusalem Pharmaceutical Co's Buyback Yield % too high?
Jerusalem Pharmaceutical Co's current Buyback Yield % is 0.00. Based on the distribution chart, Jerusalem Pharmaceutical Co ranks #999999 out of 271 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jerusalem Pharmaceutical Co has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jerusalem Pharmaceutical Co's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jerusalem Pharmaceutical Co ranks #999999 out of 271 companies for Buyback Yield %. This places Jerusalem Pharmaceutical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Jerusalem Pharmaceutical Co and its competitors. Jerusalem Pharmaceutical Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jerusalem Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co (XPAE:JPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.41, compared to a current price of $3.65 — trading 51.5% above its estimated fair value. The current Buyback Yield % is 0.00. Jerusalem Pharmaceutical Co's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Jerusalem Pharmaceutical Co (XPAE:JPH), the current Buyback Yield % is 0.00 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jerusalem Pharmaceutical Co (XPAE:JPH) Overvalued in 2026?
Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co stock appears to be overvalued.
The current stock price of $3.65 is trading 51.5% above its estimated GF Value™ of $2.41.
GuruFocus considers Jerusalem Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for XPAE:JPH:
Buyback Yield %: 0.00
GF Value™: $2.41 vs. price of $3.65 (51.5% above fair value)
No single metric tells the full story. See the XPAE:JPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jerusalem Pharmaceutical Co is engaged in developing, manufacturing and marketing of human pharmaceuticals products. It also produces detergent, cosmetic, personal and home care products, veterinary and agricultural products. The company operates in Jordan, Algeria, the Middle East, and North Africa Region. Its product portfolio contains more than 300 pharmaceutical products in various dosage forms including tablets, capsules, sterile injectables, powders for suspensions, suspensions, syrups, powders, suppositories, ovules, creams, ointments, as well as ear and nose drops and solutions.
82GF Score
Get the complete analysis for XPAE:JPH
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:JPH has been successfully added to your 
